Sandoz Researching Four Drugs to Treat Alzheimer's Disease

By Levine, Karen | Drug Topics, February 8, 1993 | Go to article overview
Save to active project

Sandoz Researching Four Drugs to Treat Alzheimer's Disease

Levine, Karen, Drug Topics

For both patient and caregiver, Alzheimer's disease has been characterized as the disease from Hell, noted William Mino, director of new product management, central nervous system and pulmonary medicine, Sandoz Pharmaceuticals Corp. By the year 2000, he told reporters at a media briefing sponsored by the National Pharmaceutical Council, six million people will be diagnosed with Alzheimer's. The cost to society in 1990 for this disease was upwards of $88 million, he added. (See related article on Alzheimer's disease in the Dec. 14 issue of Drug Topics.)

Mino defined Alzheimer's disease as a type of dementia involving global impairment of intellect or personality without an impairment of consciousness--a multifactorial disease that affects behavioral, cognitive, and quality-of-life issues. Very little is known about the pathophysiology of the disease, he went on, so there is little effective therapy.

Mino related that autopsy of Alzheimer's patients reveals a decrease of acetylcholine in the brain. "There is a problem with the acetylcholine system," he said. But, he added, "it is difficult to say if Alzheimer's is the cause of decreased acetylcholine in the brain or if the decrease in acetylcholine in the brain causes Alzheimer's disease "

Acetylcholine, a prevalent neurotransmitter in the human body, helps the nerve impulses to jump to another nerve or muscle, Mino explained.

According to Mino, Sandoz is currently researching the following four drug compounds for the treatment of Alzheimer's disease:

* SDZ ENA 713

* ENX 792

* SDZ ENS 163

* SDZ 21094

None of the drugs have generic or brand names at this time, he noted.

During a follow-up interview with Drug Topics, Mino explained that SDZ ENA 713 is an acetylcholinesterase inhibitor. Acetylcholin-esterase, he indicated,. is an enzyme that breaks down acetylcholine; inhibiting this enzyme, as in the case of SDZ ENA 713, increases the brain stores of available acetylcholine.

Mino noted that SDZ ENA 713 has just completed phase I clinical trials and is entering phase II trials. The drug has been given orally in doses of up to 6 mg per day and has been well tolerated. Currently, there is a 300-patient study under way in Europe, the researcher disclosed, and mild to moderate adverse reactions--among them digestive disturbances, nausea/vomiting, and dizziness--have been reported with the investigational use of the drug.

The rest of this article is only available to active members of Questia

Sign up now for a free, 1-day trial and receive full access to:

  • Questia's entire collection
  • Automatic bibliography creation
  • More helpful research tools like notes, citations, and highlights
  • Ad-free environment

Already a member? Log in now.

Notes for this article

Add a new note
If you are trying to select text to create highlights or citations, remember that you must now click or tap on the first word, and then click or tap on the last word.
Loading One moment ...
Project items
Cite this article

Cited article

Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

Cited article

Sandoz Researching Four Drugs to Treat Alzheimer's Disease


Text size Smaller Larger
Search within

Search within this article

Look up

Look up a word

  • Dictionary
  • Thesaurus
Please submit a word or phrase above.
Print this page

Print this page

Why can't I print more than one page at a time?

While we understand printed pages are helpful to our users, this limitation is necessary to help protect our publishers' copyrighted material and prevent its unlawful distribution. We are sorry for any inconvenience.
Full screen

matching results for page

Cited passage

Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

Cited passage

Welcome to the new Questia Reader

The Questia Reader has been updated to provide you with an even better online reading experience.  It is now 100% Responsive, which means you can read our books and articles on any sized device you wish.  All of your favorite tools like notes, highlights, and citations are still here, but the way you select text has been updated to be easier to use, especially on touchscreen devices.  Here's how:

1. Click or tap the first word you want to select.
2. Click or tap the last word you want to select.

OK, got it!

Thanks for trying Questia!

Please continue trying out our research tools, but please note, full functionality is available only to our active members.

Your work will be lost once you leave this Web page.

For full access in an ad-free environment, sign up now for a FREE, 1-day trial.

Already a member? Log in now.

Are you sure you want to delete this highlight?